Management of borderline resectable NSCLC: a narrative review.
Evidence is growing for combining surgery with newer immunotherapy drugs to treat lung cancer that previously seemed inoperable.
This narrative review from Spanish oncology centers synthesizes evidence on managing borderline resectable NSCLC, an area in rapid evolution due to neoadjuvant immunotherapy trials. The review addresses patient selection, multimodal staging, and emerging perioperative treatment strategies.
What the study was
- Study design
- Narrative review
- Population
- Borderline resectable NSCLC patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical & translational oncology
Why it surfaced
Practical review on evolving NSCLC perioperative management; standard clinical content without new primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.